Drug Trial Radar · NCT03043872
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
987
Actual
Start
Mar 27, 2017
Primary completion
Jan 27, 2020
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer
Conditions
- Small Cell Lung Carcinoma Extensive Disease
Interventions
DurvalumabDrug
IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
TremelimumabDrug
IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
CarboplatinDrug
up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
CisplatinDrug
up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
EtoposideDrug
up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EPTime frame: From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).
- OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EPTime frame: From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
- OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EPTime frame: From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months).
- OS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EPTime frame: From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Locations
207 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Scottsdale, Arizona
Research Site
Rogers, Arkansas
Research Site
Santa Monica, California
Research Site
New Haven, Connecticut
Research Site
Athens, Georgia
Research Site
Fort Wayne, Indiana
Research Site
Muncie, Indiana
Research Site
Leawood, Kansas
Research Site
Wichita, Kansas
Research Site
Paducah, Kentucky
Research Site
Grand Rapids, Michigan
Research Site
Mineola, New York
Research Site
Cleveland, Ohio
Research Site
Columbus, Ohio
Research Site
Harrisburg, Pennsylvania
Research Site
Sioux Falls, South Dakota
Research Site
Nashville, Tennessee
Research Site
Kennewick, Washington
Research Site
Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Linz, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Barretos, Brazil
Research Site
Curitiba, Brazil
Research Site
Passo Fundo, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
Santo André, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
Panagyurishte, Bulgaria
Research Site
Plovdiv, Bulgaria
Showing 40 of 207 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.